Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 16,120 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorders Clear all
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

NCT00915551
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 (Ingenol Mebutate) gel, 0.015%, Vehicle Gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Hot Springs, Arizona • Fremont, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 30, 2026, 12:48 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

NCT02706951
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Upadacitinib, Placebo Upadacitinib, Placebo Methotrexate
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
52
States / cities
Huntsville, Alabama • Mobile, Alabama • Gilbert, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 30, 2026, 12:48 AM EDT
Completed Phase 2 Interventional Results available

Stellate Ganglion Block (SGB) For Women for Breast Cancer

NCT02513329
View directory record Official record
Conditions
Hot Flushes, Hot Flashes
Interventions
Bupivicaine, Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 70 Years · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 30, 2026, 12:48 AM EDT
Completed Phase 3 Interventional Results available

Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery

NCT00542542
View directory record Official record
Conditions
Breast Cancer
Interventions
Paravertebral Block, Propofol, Fentanyl, Ropivacaine, Midazolam
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 30, 2026, 12:48 AM EDT
Completed Phase 1 Interventional

Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate

NCT01329991
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PLX5622, Placebo
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Anniston, Alabama • Lansing, Michigan • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 30, 2026, 12:48 AM EDT
Completed Not applicable Interventional Results available

Mammosite Breast Brachytherapy Optimization in the Treatment of Breast Carcinoma

NCT00611624
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Mammosite brachytherapy radiation
Radiation
Lead sponsor
Yale University
Other
Eligibility
50 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 30, 2026, 12:48 AM EDT
Completed Phase 1 Interventional

STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain

NCT01904123
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Recurrent Brain Neoplasm, Recurrent Glioblastoma, Recurrent Malignant Glioma
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, STAT3 Inhibitor WP1066
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 30, 2026, 12:48 AM EDT
Completed Phase 2 Interventional Results available

Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer

NCT00324259
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Estradiol
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
7
States / cities
Chicago, Illinois • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 30, 2026, 12:48 AM EDT
Terminated Phase 2 Interventional

A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma

NCT00402662
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
everolimus, Imatinib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 30, 2026, 12:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hormonal Effects on Tc-99m Sestamibi Uptake in the Breast

NCT00943527
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 45 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Oct 30, 2026, 12:48 AM EDT
Active, not recruiting Phase 2 Interventional

Treating Patients With Melanoma and ALK Alterations With Ensartinib

NCT03420508
View directory record Official record
Conditions
Melanoma
Interventions
Ensartinib, ALKATI by Customized Nanostring Assay
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Middletown, New Jersey • Montvale, New Jersey • East White Plains, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 30, 2026, 12:48 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury

NCT01910818
View directory record Official record
Conditions
Chronic Radiation Dermatitis
Interventions
Fractional CO2 laser treatment, No treatment
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 30, 2026, 12:48 AM EDT
Not listed Phase 2 Interventional

Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma

NCT02142335
View directory record Official record
Conditions
Malignant Melanoma of Skin Stage III, Metastatic Melanoma
Interventions
Rituxan
Drug
Lead sponsor
California Cancer Assocaties for Research & Excellence
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 30, 2026, 12:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting

NCT00412425
View directory record Official record
Conditions
Melanoma
Interventions
Palonosetron
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2012 · Synced Oct 30, 2026, 12:48 AM EDT
Completed Phase 2 Interventional

Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer

NCT00193076
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Carboplatin, Trastuzumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Oct 30, 2026, 12:48 AM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia

NCT00627276
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
omega-3 fatty acid, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 30, 2026, 12:48 AM EDT
Completed No phase listed Observational

Salivary Biomarkers for Sjögren's Syndrome Detection

NCT01807689
View directory record Official record
Conditions
Sjögren's Syndrome
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 30, 2026, 12:48 AM EDT
Completed Not applicable Interventional

Educational Intervention to Improve Patient-Physician Awareness of Cardiovascular Risk in Rheumatoid Arthritis.

NCT03495791
View directory record Official record
Conditions
Rheumatoid Arthritis, Arthritis, Rheumatoid
Interventions
YouTube Video
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 30, 2026, 12:48 AM EDT
Recruiting Phase 1Phase 2 Interventional

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

NCT07064018
View directory record Official record
Conditions
Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Ovarian Cancer, KRAS Mutation-Related Tumors
Interventions
Spedox-6, Pegfilgrastim, Filgrastim
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 30, 2026, 12:48 AM EDT
Terminated No phase listed Observational

Surviving Daily Life

NCT07054723
View directory record Official record
Conditions
Stress, Cognitive Change, Breast Cancer, Breast Carcinoma, Breast Neoplasm, Cognitive Dysfunction
Interventions
Mobile Daily Diary
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
40 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 12:48 AM EDT
Active, not recruiting Not applicable Interventional

The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study

NCT05489588
View directory record Official record
Conditions
Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Interventions
GORE® VIAFORT Vascular Stent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
24
States / cities
Stanford, California • Darien, Connecticut • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 12:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab

NCT02515227
View directory record Official record
Conditions
Melanoma
Interventions
6MHP, Pembrolizumab
Biological · Drug
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 30, 2026, 12:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

NCT01962103
View directory record Official record
Conditions
Neuroblastoma, Rhabdomyosarcoma, Ewing's Sarcoma, Ewing's Tumor, Sarcoma, Ewing's, Sarcomas, Epitheliod, Sarcoma, Soft Tissue, Sarcoma, Spindle Cell, Melanoma, Malignant Melanoma, Clinical Oncology, Oncology, Medical, Pediatrics, Osteosarcoma, Osteogenic Sarcoma, Osteosarcoma Tumor, Sarcoma, Osteogenic, Tumors, Cancer, Neoplasia, Neoplasm, Histiocytoma, Fibrosarcoma, Dermatofibrosarcoma
Interventions
nab-paclitaxel
Drug
Lead sponsor
Celgene
Industry
Eligibility
6 Months to 24 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 30, 2026, 12:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Single-Center, Clinical Study to Evaluate the Safety of a Non-Fragranced Personal Lubricant in Healthy Female Subjects

NCT02320227
View directory record Official record
Conditions
Erythema, Edema
Interventions
Miami w/o frag Personal lubricant
Device
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 30, 2026, 12:48 AM EDT